Feedback Share Discussion Threads

[ged5] 21/11/2019 10:58

Hi Dp, Sectra could be considered a negative if FDBK were trying to put Cadran in place. They're not! Sectra are providing the PACS and seem pretty good at it. They are the preferred provider of the PACS to replace GE healthcare's PACS.



I also thought it was a negative so I have emailed for clarification but you'll find this in the public domain somewhere:-
The USP of Bleepa is that it facilitates image based communication between frontline clinical teams through mobile devices which other vendors do not do.

I now think this could be excellent news but time will tell.

[dplewis1] 21/11/2019 10:44

Hi Ged sorry for my ignorance - someone touted the Sectra news as negative for FDBK as it would be competition. So Sectra isn't a way to send and receive medical images and could actually end up being used alongside Bleepa you think?

[ged5] 21/11/2019 10:19

The pilot study with the Pennine Trust might just be more important than we're giving it credit for.

Sectra have been appointed as the preferred provider to supply a picture archiving and communication system (PACS) and a vendor neutral archive (VNA) across Greater Manchester.

It was confirmed to Digital Health News by the Greater Manchester Health and Social Care Partnership that the procurement of the two systems began in February 2019.

This includes the Pennine trust.

So if Bleepa is used to complement the Sectra PACS and it is proven to be a success, could a partnership emerge? And how many more leads could it give for Bleepa. Sectra UK now has more than 50 customers including some of the biggest UK trusts.

I might be going ahead of myself with the thinking here but there does seem to be incredible potential.

[ducatiman] 20/11/2019 11:02

Possibly Dave as the mms will buy in quantity currently

[dave4545] 20/11/2019 10:20

Seller done yet ?

375k max online but at 0.96p so nicely under the spread

Infact online is decent atm 0.93-0.96p

[ducatiman] 19/11/2019 19:53

Only a matter of time LR2. Used in over 60 research institutes worldwide. Cancer research UK early detection award.

[lr2] 19/11/2019 18:31

Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: A systematic review.



Texrad used on GE and Siemens hardware.

[davydoo] 19/11/2019 16:06

I managed to get 800k, now up to 2.4m

[dave4545] 19/11/2019 14:41

I'm a buyer at any 0.9p but each time it touches it either there is no size offered or others beat me to the punch.

Leave a limit next time

[davydoo] 19/11/2019 14:30

nice to be buying below 0.95p again

[purple11] 19/11/2019 13:28

...and flush....

[ducatiman] 19/11/2019 12:57

Cheap enough yet Dr.T? You wouldn't want to "miss an opportunity"!

[davydoo] 19/11/2019 09:43

who votes with 1818 shares against everything? That's £20 worth

[ged5] 19/11/2019 09:24

Regina61, mothball:-stop using (a piece of equipment or a building) but keep it in good condition so that it can readily be used again.

RNS 18-11-19:-

"We have made some product modifications to TexRAD Research in response to customer feedback and are evaluating the impact of these on revenue. In the near term, we will continue to sell TexRAD within the research setting through third party distributors which provides a more cost-effective avenue for maintaining our sales efforts.

The company have thought about the strategy!

[yump] 19/11/2019 08:48

Texrad is not mothballed. That is simply incorrect. Its the fda compliance effort that will not be taking up resources. If they think bleepa has become a much better prospect then it would be a mistake to commit more resources to texrad, where even after fda approval, US sales might not happen without a lot of cost.

There are if course a lot of what ifs. So the issue is really can you see how bleepa might be different or not ?

Of course there wont be a sales forecast.

Also, if the product is unique, there cannot be a comparison with a competitor. Thats the thing about new inventions I believe.

Barriers to entry - yes that is a possible issue - IP protection etc

[regina61] 19/11/2019 08:30

This Company raised millions over the past couple of years for the development of TexRad. It hasn't happened and now TexRad is effectively mothballed. Meanwhile the new non-shareholding CEO is spending what's left of the cash on a speculative and unproven product which didn't exist nine months ago and where no sales are currently in prospect, (where is the sales forecast ?) If this gamble fails, (and how is it anything more when there is no objective evaluation of its performance in relation to competitors, what are the barriers to entry etc etc?) what will be the consequences for the Board? Compare and contrast that with the long suffering shareholders...

[coldspring] 18/11/2019 17:25

Someone wanted out selling a million shares in less than a minute. Smacks of manipulation for sure.

[yump] 18/11/2019 16:55

Hopefully nth. time lucky, although the 'n' is a lot higher than it should be !

[czc9] 18/11/2019 12:53

Thanks you too. I genuinely hope it's comes good because I've been here for years and know many lths. GL

[dplewis1] 18/11/2019 12:44

Ah ok thanks digger, I couldn't find the timings on any RNS. Hopefully someone goes!

[digger2779] 18/11/2019 12:27

dplewis1 - it starts at 3pm or 4pm my time as am in Spain. I won't be going lol.

[dplewis1] 18/11/2019 12:11

Has the AGM finished now? Was anyone there?

[yump] 18/11/2019 11:45

Seems to me that if they've got IP on Bleepa and its system agnostic, then there may be opportunities to licence in some way, as licencees of various types will have way more access to customers than FDBK ploughing along with their own sales process.

[ged5] 18/11/2019 11:13

OK CZ, best of luck to you.

[ged5] 18/11/2019 10:59

Thanks Phurley.

For example, the transfer of images does not give the radiologist receiving the images the opportunity to follow up with other patient procedures. Therefore, they must convey the appropriate information to the on-site doctors. This is not always effective and can often lead to miscommunication and confusion.

Furthermore, teleradiology is entirely dependent on technology so should there be no access to the internet (e.g. if the hospital’s internet is down for service), teleradiology is no longer an option and patients will remain undiagnosed or even untreated.



Seems like they need Bleepa!